🇺🇸 FDA
Patent

US 11052073

Sphingosine kinase 2 inhibitor for treating coronavirus infection

granted A61KA61K31/435A61K31/4409

Quick answer

US patent 11052073 (Sphingosine kinase 2 inhibitor for treating coronavirus infection) held by RedHill Biopharma Ltd. expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
RedHill Biopharma Ltd.
Grant date
Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/435, A61K31/4409, A61K31/495, A61K9/0053